Overview

Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
0
Participant gender:
All
Summary
This purpose of this study is to investigate the effects of mirabegron on the cardiovascular system in patients with overactive bladder with current or a history of cardiovascular disease.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Mirabegron
Criteria
Inclusion Criteria:

- having coexisting cardiovascular disease or a history of cardiovascular diseases

- having electrocardiogram record conducted within seven days before the start of the
mirabegron treatment (including the first day of administration)

Exclusion Criteria:

- having serious cardiovascular disease

- having significant long QT (QTc > 500 msec)